Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
H-PRIME pragmatic hydroxyurea trial in children with sickle cell anaemia
PACTR202401802272880Phase 3Recruiting
- Sponsor
- Imperial College London
- Start
- Sep 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of hydroxyurea in sickle cell anemia (SCA) (2 arms), sponsored by Imperial College London. Primary endpoints: All-cause mortality, Malaria-associated hospitalisations and 1 more. Started Sep 2023; status: recruiting.
02
Drugs
hydroxyurea
03
Conditions
sickle cell anemia (SCA)
Beyond the preview
Go deeper on PACTR202401802272880.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202401802272880.